Invesco Ltd. Protagonist Therapeutics, Inc Transaction History

Invesco Ltd.

$516 Billion
Q4 2024

A detailed history of Invesco Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Invesco Ltd. holds 738,952 shares of PTGX stock, worth $28.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

738,952

Previous 653,152 13.14%

Holding current value

$28.6 Million

Previous $29.4 Million 2.82%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$38.51 - $48.43 $3.3 Million - $4.16 Million	85,800 Added 13.14%	738,952 $28.5 Million
Q3 2024 Nov 12, 2024	BUY	$33.72 - $47.33 $19 Million - $26.7 Million	564,718 Added 638.58%	653,152 $29.4 Million
Q2 2024 Aug 13, 2024	BUY	$24.66 - $34.8 $1.48 Million - $2.09 Million	60,075 Added 211.84%	88,434 $3.06 Million
Q1 2024 May 14, 2024	SELL	$21.79 - $32.15 $379,233 - $559,538	-17,404 Reduced 38.03%	28,359 $820,000
Q4 2023 Feb 12, 2024	BUY	$14.05 - $23.44 $68,311 - $113,965	4,862 Added 11.89%	45,763 $1.05 Million
Q3 2023 Nov 13, 2023	SELL	$16.68 - $23.66 $3.73 Million - $5.29 Million	-223,510 Reduced 84.53%	40,901 $682,000
Q2 2023 Aug 11, 2023	SELL	$18.02 - $29.36 $243,720 - $397,094	-13,525 Reduced 4.87%	264,411 $7.3 Million
Q1 2023 May 12, 2023	BUY	$10.78 - $25.38 $2.66 Million - $6.25 Million	246,384 Added 780.88%	277,936 $6.39 Million
Q4 2022 Feb 13, 2023	BUY	$7.36 - $11.17 $20,814 - $31,588	2,828 Added 9.85%	31,552 $344,000
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $6,122 - $9,122	-779 Reduced 2.64%	28,724 $242,000
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $3,692 - $13,346	-523 Reduced 1.74%	29,503 $233,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $238,091 - $368,052	10,201 Added 51.46%	30,026 $711,000
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $46,314 - $97,461	-2,627 Reduced 11.7%	19,825 $678,000
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $56,073 - $215,157	4,330 Added 23.89%	22,452 $398,000
Q2 2021 Aug 17, 2021	BUY	$25.57 - $44.88 $205,045 - $359,892	8,019 Added 79.37%	18,122 $814,000
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $192,159 - $314,708	10,103 New	10,103 $262,000
Q4 2020 Feb 16, 2021	SELL	$18.49 - $25.13 $3.5 Million - $4.76 Million	-189,232 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $684,294 - $1.01 Million	-45,049 Reduced 19.23%	189,232 $3.7 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $924,482 - $2.81 Million	149,351 Added 175.85%	234,281 $4.14 Million
Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $458,622 - $783,054	84,930 New	84,930 $599,000
Q4 2019 Feb 14, 2020	SELL	$4.69 - $13.45 $298,532 - $856,132	-63,653 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $199,454 - $351,005	-21,196 Reduced 24.98%	63,653 $764,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $121,553 - $175,426	13,536 Added 18.98%	84,849 $1.03 Million
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $463,534 - $981,980	71,313 New	71,313 $896,000

Others Institutions Holding PTGX

# of Institutions

254

Shares Held

58.9M

Call Options Held

226K

Put Options Held

218K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.9B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account